NCT02164461View on ClinicalTrials.gov

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 4, 2015

Primary Completion Date

March 8, 2017

Study Completion Date

March 8, 2017

Conditions
Effects of ImmunotherapyMetastatic/Recurrent Cervical CancerCervical AdenocarcinomaCervical Adenosquamous Cell CarcinomaCervical Squamous Cell CarcinomaCervical Small Cell CarcinomaStage III Cervical CancerStage IVA Cervical CancerStage IVB Cervical Cancer
Interventions
BIOLOGICAL

Axalimogene filolisbac

Trial Locations (2)

30912

Augusta

Unknown

Charlottesville

Sponsors

Lead Sponsor

Advaxis, Inc.
All Listed Sponsors
lead

Advaxis, Inc.

INDUSTRY

NCT02164461 - Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer | Biotech Hunter | Biotech Hunter